Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study
Damien Fournier, Romain Carrière, Maxime Bour, Emilie Grisot, Pauline Triponney, Cédric Muller, Jérôme Lemoine, Katy Jeannot, Patrick Plésiat, the GERPA Study Group
Abstract
Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) of the isolates were resistant to both ceftazidime and imipenem.
Topics & Concepts
CeftazidimeImipenemPseudomonas aeruginosaMicrobiologyCeftazidime/avibactamTazobactamPopulationBiologyMedicineAntibioticsAntibiotic resistanceBacteriaEnvironmental healthGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory Infections